Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pucotenlimab + lenvatinib
- Development stage
- Unknown
- Lead developer
- Taizhou Hanzhong biomedical co. LTD
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pucotenlimab + lenvatinib is an investigational combination therapy consisting of pucotenlimab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), and lenvatinib, a small molecule multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET proto-oncogene, and KIT proto-oncogene. Pucotenlimab acts as an immune checkpoint inhibitor to enhance anti-tumor immune responses by blocking the PD-1/PD-L1 pathway. Lenvatinib inhibits angiogenesis and tumor proliferation through its action on multiple tyrosine kinases involved in tumor vascularization and growth. The combination is being studied primarily for advanced hepatocellular carcinoma (aHCC) and unresectable intrahepatic cholangiocarcinoma as conversion or neoadjuvant therapy[2][3][5][7].
- Brand names
- LenvimaPuyouheng
- Other names
- HX008 (for pucotenlimab)
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR2 (Keratinocyte growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on pucotenlimab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pucotenlimab + lenvatinib.